Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 5/20 | 1.00 |
| ▸ | COMT | P21964 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BRD2 | P25440 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22494156 | 0.82 | PIK3CD (0.70) | PIK3CDNPC1RAB9AL3MBTL1BRD4 | |
| SCHEMBL18609944 | 0.82 | PIK3CD (0.70) | PIK3CDBRD4BRD2DPP4 | |
| SCHEMBL25664018 | 0.82 | PIK3CD (0.70) | PIK3CDNPC1RAB9AL3MBTL1BRD4 | |
| SCHEMBL18926693 | 0.80 | PIK3CD (0.67) | PIK3CDCOMTNPC1RAB9AL3MBTL1 | |
| SCHEMBL31477250 | 0.79 | PIK3CD (0.66) | PIK3CDBRD4BRD2 | |
| SCHEMBL3419405 | 0.78 | PIK3CD (0.65) | PIK3CDCOMTNPC1RAB9AL3MBTL1 | |
| SCHEMBL21959946 | 0.78 | PIK3CD (0.65) | PIK3CDCOMTNPC1RAB9AL3MBTL1 | |
| SCHEMBL1156274 | 0.77 | PIK3CD (0.62) | PIK3CDBRD4BRD2MEN1KMT2A | |
| SCHEMBL19229725 | 0.76 | PIK3CD (0.61) | PIK3CDCOMTNPC1RAB9AL3MBTL1 | |
| SCHEMBL23328920 | 0.75 | PIK3CD (0.60) | PIK3CDBRD4BRD2KMT2ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230203015-A1 | MAP KINASE KINASE (MKK7) INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| US-20230012600-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF | BROADENBIO CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| EP-4105217-A1 | 3-((8-((1H-PYRAZOL-4-YL)AMINO)IMIDAZO[1,2-A]PYRIDIN-3-YL)ETHINYL)-N-PHENYLBENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021083011-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVE AND USE THEREOF | 北京伯汇生物技术有限公司 | 2021-05-06 | — | — | WO | disclosed |
| US-9988386-B2 | Compounds for treatment of diseases of abnormal angiogenesis or aberrant growth factors and uses thereof | Kata Pharmaceuticals, Inc. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180037573-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2018-02-08 | — | — | US | disclosed |
| US-20180037572-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2018-02-08 | — | — | US | disclosed |
| US-20170129876-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2017-05-11 | — | — | US | disclosed |
| US-9630963-B2 | Quinolone derivatives as fibroblast growth factor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630963-B2 | Quinolone derivatives as fibroblast growth factor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9580421-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160137646-A1 | Novel Compounds and Uses Thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160130268-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160060264-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2016-03-03 | — | — | US | disclosed |
| US-9212145-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150072986-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2015-03-12 | — | — | US | disclosed |
| WO-2014182829-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072986-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | PIK3CD 1425/4885COMT 3384/4885NPC1 3661/4885 |
| US-20160137646-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | PIK3CD 516/4885COMT 2599/4885NPC1 2935/4885 |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | PIK3CD 1633/4885COMT 3253/4885NPC1 1407/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | PIK3CD 3670/4885COMT 3584/4885NPC1 128/4885 |
| US-20230203015-A1 | MAP KINASE KINASE (MKK7) INHIBITORS AND USES THEREOF | MAP2K7, MAP3K7, MAPK7 | PIK3CD 2379/4885COMT 1021/4885NPC1 1722/4885 |
| US-20180037572-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | PIK3CD 1425/4885COMT 3384/4885NPC1 3661/4885 |
| US-20160130268-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | PIK3CD 370/4885COMT 2762/4885NPC1 2860/4885 |
| US-20180037573-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | PIK3CD 1425/4885COMT 3384/4885NPC1 3661/4885 |
| US-20230012600-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF | FGFR4, FGFR1, FGFR3 | PIK3CD 815/4885COMT 3480/4885NPC1 1946/4885 |
| US-20170129876-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | PIK3CD 1425/4885COMT 3384/4885NPC1 3661/4885 |
| US-20160060264-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | PIK3CD 1425/4885COMT 3384/4885NPC1 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.